This resource is no longer available

Social and economic factors and health behaviors alone are attributable to 70% of poor health outcomes.

Therefore, FDA guidance recommends including a diversity plan in all cases where clinical studies are required to support regulatory submission of medical products.

Watch this on-demand webinar to access 3 keys to designing representative clinical trials.

Vendor:

Inovalon, Inc.

Premiered:

Feb 3, 2024

Format:

HTML

Type:

Webcast